Big Pharma Split Corp

Big Pharma Split Corp

Big Pharma Split Corp
Date Symbol NAV($)
  • Distribution
  • Total($)

Fund Quick Facts January 31, 2018

Cusip PRM 08934P108
Cusip PRM.PR.A 08934P207
Total AUM $32.5 million
Management Fee 0.75%
Total Holdings 13
Income Distribution PRM Monthly
Income Distribution PRM.PR.A Quarterly
Distribution PRM $0.1031
Distribution PRM.PR.A $0.1250
Distribution Method Cash

Top Ten Holdings

January 31, 2018

Security Portfolio (%)
AbbVie Inc. 10.9
GlaxoSmithKline PLC ADR 10.0
Amgen Inc. 9.9
AstraZeneca PLC ADR 9.9
Novo Nordisk A/S 9.9
Pfizer Inc. 9.5
Bristol-Myers Squibb Company 9.3
Johnson & Johnson    9.2
Eli Lilly and Company 8.8
Merck & Co., Inc. 7.1

Fund Overview

The Company will invest in an initially equally-weighted portfolio comprised of Equity Securities of ten issuers, selected by the Portfolio Manager from the Investable Universe, that at the time of investment and immediately following each semi-annual reconstitution and rebalancing: (i) are listed on a North American exchange; (ii) pay a dividend; and (iii) have options in respect of its Equity Securities that, in the opinion of the Portfolio Manager, are sufficiently liquid to permit the Portfolio Manager to write options in respect of such securities. The Portfolio will be comprised primarily of the largest (as determined by market capitalization calculated in US$) Pharmaceutical Issuers in the Investable Universe.

The Manager will hedge substantially all of the Portfolio’s U.S dollar exposure back to the Canadian dollar.

The Class A Shares provide holders a monthly cash distribution and are targeted to be $0.1031 per share and, for the Preferred Shares, quarterly cash distributions are fixed at $0.1250 per share.  


Link to prospectus Quarterly Summary

Link to prospectus Prospectus Eng | Fr

Portfolio Management

Paul MacDonald Harvest Portfolios Group Inc.


Chief Investment Officer


Portfolio Manager


Portfolio Manager

Investor Suitability

Investors seeking income through investment in the world's leading pharmaceutical companies.

Investors seeking to hold their investment for medium to long term.



Cumulative Growth $10,000 Invested

January 31, 2018 (NAV pricing)

We are unable to provide year by year returns because the fund has not existed a full calendar year
We are unable to provide year by year returns because the fund has not existed a full calendar year

Historical Prices



Historical Distributions
(designated as "eligible" dividends unless the company indicates otherwise) 



Portfolio Holdings

Big Pharma Split Corp
Quarterly Portfolio Holdings
as of December 31 2017

Security % of Portfolio
AstraZeneca PLC ADR 10.1
Novo Nordisk A/S 9.9
GlaxoSmithKline PLC ADR 9.8
AbbVie Inc. 9.7
Pfizer Inc. 9.7
Amgen Inc. 9.6
Johnson & Johnson 9.6
Bristol-Myers Squibb Company 9.5
Eli Lilly and Company 9.4
Merck & Co., Inc. 6.9
Cash and other assets and liabilities 5.8
Class J Shares 0.0
Foreign Currency Schedule 0.0
Options 0.0
Preferred Shares 0.0

Financial Documents



Harvest Portfolios Group Proxy Voting Securities Policy

November 24, 2017 to June 30, 2018

November 24, 2017 to June 30, 2018 Proxy Summary

Tax Information


You will usually pay brokerage fees to your dealer if you purchase or sell shares of the Fund on the TSX. If shares are purchased or sold on the TSX, investors may pay more than the current net asset value when buying shares of the Fund and may receive less than the current net asset value when selling them. There are ongoing fees and expenses associated with owning shares of an investment fund. An investment fund must prepare disclosure documents that contain key information about the fund. You can find more detailed information about the fund in these documents. Investment funds are not guaranteed, their values change frequently and past performance may not be repeated. Distributions are paid to you in cash from the Class A or Preferred Class of the Fund. If the Fund earns less than the amount distributed, the difference is a return of capital. The current yield is calculated based on the market price of the Fund. The information contained herein is not an offer to sell nor a solicitation to buy any security. Such an offer can only be made by prospectus or other applicable offering document.